- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved
- On Track to Regain Compliance with All Nasdaq Listing Requirements
- No Variable Priced Securities are Outstanding
- Warrant Overhang Near Elimination
- Allarity Withdraws its Form S-1
- Establishes Equity of $15 Million
- Cash Balance of $14 Million
Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024.
Comments